[go: up one dir, main page]

PE20220578A1 - Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades - Google Patents

Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades

Info

Publication number
PE20220578A1
PE20220578A1 PE2021002219A PE2021002219A PE20220578A1 PE 20220578 A1 PE20220578 A1 PE 20220578A1 PE 2021002219 A PE2021002219 A PE 2021002219A PE 2021002219 A PE2021002219 A PE 2021002219A PE 20220578 A1 PE20220578 A1 PE 20220578A1
Authority
PE
Peru
Prior art keywords
alkyl
cycloalkyl
imidazo
diseases
treatment
Prior art date
Application number
PE2021002219A
Other languages
English (en)
Inventor
Emily Anne Peterson
Ryan Evans
Fang Gao
Philippe Bolduc
Magnus Pfaffenbach
Zhili Xin
Tricia May-Dracka
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of PE20220578A1 publication Critical patent/PE20220578A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)

Abstract

La presente invencion esta referida a compuestos derivados de imidazo[1,2-a]piridinilo de formula (I), en donde R1 se selecciona de halo, alquilo C1-5, cicloalquilo C3-6, -alquilo C1-2-cicloalquilo C3-6, un heterociclo de 4 a 7 miembros que contiene 1 a 2 heteroatomos seleccionados de forma independiente de N, S y O entre otros; R2 es hidrogeno, alquilo C1-4 o halogeno; R3 se selecciona de un heteroarilo de 5 o 6 miembros con 1 a 3 heteroatomos seleccionados de N, O y S, fenilo, un heterociclo de 5-6 miembros parcial o completamente saturado con 1 a 2 heteroatomos, un cicloalquilo C3-6 parcial o completamente saturado, entre otros; X1 y X2 se seleccionan de N, CH y CR5, en donde solamente uno de X1 o X2 puede ser N. Dichos compuestos inhiben la actividad de IRAK4 (cinasas asociadas al receptor de interleucina 4 ). Tambien refiere a una composicion farmaceutica que los comprende, siendo utiles en el en el tratamiento y el control de enfermedades o trastornos que incluyen una enfermedad inflamatoria, una enfermedad autoinmunitaria, cancer, una enfermedad cardiovascular, entre otros.
PE2021002219A 2019-06-27 2020-06-24 Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades PE20220578A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962867589P 2019-06-27 2019-06-27
PCT/US2020/039359 WO2020263980A1 (en) 2019-06-27 2020-06-24 Imidazo[1,2-a]pyridinyl derivatives and their use in the treatment of disease

Publications (1)

Publication Number Publication Date
PE20220578A1 true PE20220578A1 (es) 2022-04-20

Family

ID=71528117

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021002219A PE20220578A1 (es) 2019-06-27 2020-06-24 Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades

Country Status (21)

Country Link
US (1) US20230087118A1 (es)
EP (1) EP3990454A1 (es)
JP (1) JP7576581B2 (es)
KR (1) KR20220027196A (es)
CN (1) CN114245796B (es)
AR (1) AR119234A1 (es)
AU (1) AU2020301230A1 (es)
BR (1) BR112021026350A2 (es)
CA (1) CA3145040A1 (es)
CL (1) CL2021003452A1 (es)
CO (1) CO2022000659A2 (es)
CR (1) CR20220037A (es)
IL (1) IL289164A (es)
JO (1) JOP20210322A1 (es)
MA (1) MA56390A (es)
MX (1) MX2021015498A (es)
PE (1) PE20220578A1 (es)
PH (1) PH12021553223A1 (es)
TW (1) TW202115075A (es)
UY (1) UY38766A (es)
WO (1) WO2020263980A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220089592A1 (en) * 2019-01-18 2022-03-24 Biogen Ma Inc. Imidazo[1,2-a]pyridinyl derivatives as irak4 inhibitors
US11866405B2 (en) 2020-12-10 2024-01-09 Astrazeneca Ab Substituted indazoles as IRAK4 inhibitors
US20250268877A1 (en) * 2020-12-22 2025-08-28 Biogen Ma Inc. 2h-indazole derivatives as irak4 inhibitors and their use in the treatment of disease
MX2023007511A (es) * 2020-12-22 2023-09-08 Biogen Ma Inc Derivados de imidazo[1,2-a]piridinilo como inhibidores de irak4 y su uso en el tratamiento de enfermedades.
JP7705966B2 (ja) * 2021-06-21 2025-07-10 武漢人福創新薬物研発中心有限公司 Ｇｐｒ８４アンタゴニストとしての三環式化合物
TW202321236A (zh) * 2021-07-07 2023-06-01 美商百健Ｍａ公司 用於靶向ｉｒａｋ４蛋白降解之化合物
EP4479137A1 (en) 2022-02-14 2024-12-25 Astrazeneca AB Irak4 inhibitors
HRP20251018T1 (hr) * 2022-09-08 2025-10-24 Redx Pharma Limited Kruti oblici inhibitora rock
WO2024133560A1 (en) * 2022-12-21 2024-06-27 Dark Blue Therapeutics Ltd Imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives as mllt1 and mllt3 inhibitors
EP4389747A1 (en) * 2022-12-21 2024-06-26 Dark Blue Therapeutics Ltd Imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives as mllt1 and mllt3 inhibitors
WO2024222712A1 (zh) * 2023-04-24 2024-10-31 上海赛默罗生物科技有限公司 咪唑并吡啶或咪唑并吡嗪类化合物、其制备方法、药物组合物和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858613B2 (en) 2002-02-19 2005-02-22 Pfizer Inc. Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
MX340490B (es) * 2010-07-13 2016-07-11 F Hoffmann-La Roche Ag * Derivados de pirazolo [1, 5a] pirimidina y de tieno [3, 2b] pirimidina como moduladores de la cinasa asociada al receptor de la interleucina 4 (irak4).
US10081624B2 (en) * 2014-08-26 2018-09-25 Takeda Pharmaceutical Company Limited Heterocyclic compound
US10059708B2 (en) * 2016-04-26 2018-08-28 Northwestern University Therapeutic targeting of the interleukin 1 receptor-associated kinase 4 (IRAK4) in leukemias characterized by rearrangements in the mixed lineage leukemia gene (MLL-r)
EP3642199B1 (en) * 2017-06-21 2022-04-27 F. Hoffmann-La Roche AG Benzofurans as irak4 modulators

Also Published As

Publication number Publication date
CA3145040A1 (en) 2020-12-30
CL2021003452A1 (es) 2022-08-19
MX2021015498A (es) 2022-04-20
CN114245796B (zh) 2024-07-30
MA56390A (fr) 2022-05-04
EP3990454A1 (en) 2022-05-04
US20230087118A1 (en) 2023-03-23
AU2020301230A1 (en) 2022-01-06
CR20220037A (es) 2022-06-03
IL289164A (en) 2022-02-01
JP7576581B2 (ja) 2024-10-31
WO2020263980A8 (en) 2021-03-04
TW202115075A (zh) 2021-04-16
UY38766A (es) 2021-01-29
CN114245796A (zh) 2022-03-25
WO2020263980A1 (en) 2020-12-30
AR119234A1 (es) 2021-12-01
JOP20210322A1 (ar) 2023-01-30
PH12021553223A1 (en) 2022-10-17
CO2022000659A2 (es) 2022-04-29
BR112021026350A2 (pt) 2022-05-10
KR20220027196A (ko) 2022-03-07
JP2022539373A (ja) 2022-09-08

Similar Documents

Publication Publication Date Title
PE20220578A1 (es) Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades
PE20170003A1 (es) Compuestos heterociclicos y usos de los mismos
PE20210406A1 (es) Inhibidores de inflamasoma nlrp3
CL2022000271A1 (es) Inhibidores de la fosfatasa shp2 de pirazolo(3,4-b)pirazina.
PE20160540A1 (es) Inhibidores de bromodominios
PE20230322A1 (es) Aminotiazoles sustituidos como inhibidores de dgkzeta para la activacion inmune
PE20190732A1 (es) Compuestos y composiciones como inhibidores de los receptores endosomales tipo peaje
PE20191613A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
PE20210658A1 (es) Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat)
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
PE20080527A1 (es) Derivado de pirimidina como inhibidor de la fosfatidilinositol 3-quinasa (pi3k)
PE20090370A1 (es) Derivados de heterociclo fusionado como inhibidores de quinasa
AR017852A1 (es) COMPUESTOS DE PIRAZOLO (3,4-b)PIRIDINA Y SUS SALES, UTILES COMO INHIBIDORES DE LAS PROTEINA-QUINASAS DEPENDIENTES DE CICLINA, Y LAS COMPOSICIONESFARMACEUTICAS QUE LOS CONTIENEN, EVENTUALMENTE ASOCIADOS CON UN AGENTE ANTICANCER.
PE20120058A1 (es) Derivados de imidazopirazina como inhibidores de syk
PE20191496A1 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas
PE20120534A1 (es) PIRIMIDINAS FUSIONADAS COMO INHIBIDORES DE Akt
PE20090900A1 (es) Derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol como inhibidores del receptor del factor de creciemiento de hepatocitos (met), su procedimiento de preparacion y una composicion farmaceutica que los contiene
PE20140390A1 (es) Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak
NO20061978L (no) Imidazopyridinsubstituerte tropanderivater med CCR5-reseptorantagonist aktivitet for behandling av HIV og inflammasjon
PE20200932A1 (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
PE20110560A1 (es) NUEVOS DERIVADOS DE TRIAZOLO[4,3-a]PIRIDINA, SU PROCEDIMIENTO DE PREPARACION, SU APLICACION COMO MEDICAMENTOS, COMPOSICIONES FARMACEUTICAS Y NUEVA UTILIZACION PARTICULARMENTE COMO INHIBIDORES DE MET
PE20130640A1 (es) Compuestos heterociclicos, su preparacion y su aplicacion terapeutica
AR073262A1 (es) Derivados de pirazolo[5, 1-b]oxazol, composiciones farmaceuticas que los comprenden y su uso en el tratamiento de enfermedades mediadas por antagonistas de crf1.
PE20091083A1 (es) Moduladores tieno- y furo- pirimidina del receptor de histamina h4
MX2022001161A (es) Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmaceuticas que los contienen y sus usos como agentes proapoptoticos.